This phase II , randomized clinical trial was conducted to evaluate the antibody and cell-mediated responses to a trivalent influenza vaccine administered without adjuvant ( TIV ) or adjuvanted with MF59 ( ATIV ) in previously nonvaccinated children less than 3 years of age .